PARs (protease-activated receptors) are a family of four G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. This report focuses on PAR 2 , which plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2 . Proteases cleave PAR 2 to expose a tethered ligand that binds to the cleaved receptor. Despite this irreversible activation, PAR 2 signalling is attenuated by β-arrestin-mediated desensitization and endocytosis, and by lysosomal targeting and degradation, which requires ubiquitination of PAR 2 . β-Arrestins also act as scaffolds for the assembly of multi-protein signalling complexes that determine the location and function of activated mitogen-activated protein kinases. Observations of PAR 2 -deficient mice support a role for PAR 2 in inflammation, and many of the effects of PAR 2 activators promote inflammation. Inflammation is mediated in part by activation of PAR 2 in the peripheral nervous system, which results in neurogenic inflammation and hyperalgesia.
Introduction
Proteases comprise 2% of the human genome and it is not surprising that they possess diverse biological functions ranging from the degradation of proteins in the intestinal lumen to control of the cell cycle. Certain serine proteases are signalling molecules that regulate cells by cleaving PARs (protease-activated receptors), a family of four GPCRs (G-protein-coupled receptors). The proteases that activate PARs include coagulation factors [e.g. thrombin, FVIIIa (factor VIIa), FXa], proteases from inflammatory cells (mast cell tryptase, neutrophil cathepsin G) and enzymes from epithelial tissues (trypsins). These proteases are released and generated during injury and inflammation, and PARs regulate haemostasis, inflammation, pain and repair. In view of these important functions, it is of interest to understand the mechanisms of activation and signalling of these receptors.
This report concerns PAR 2 , a receptor for trypsins, mast cell tryptase, and FVIIa and FXa. We will review the properties of proteases that activate PAR 2 , discuss the regulation of signal transduction, and review potential functions of PAR 2 . There are several comprehensive reviews of PARs [1, 2] . the extracellular N-terminus to expose a tethered ligand domain that binds to conserved regions in extracellular loop II of the receptor to initiate signalling. Synthetic hexapeptides corresponding to the tethered ligand domain (activating peptides) directly activate PAR 1 , PAR 2 and PAR 4 and are useful tools to probe receptor functions. Trypsin cleaves PAR 2 at R 34 ↓S 35 LIGKV to reveal the tethered ligand SLIGKV in humans [3, 4] .
Pancreatic trypsins
Trypsins are the most potent activators of PAR 2 [3, 6] . Trypsinogens I and II, and mesotrypsinogen are the major trypsinogen genes in the human pancreas [8, 9] . Trypsinogens I and II are the principal forms secreted in pancreatic juice, are activated by enteropeptidase in the small intestine and participate in digestion. Pancreatic trypsin may be a physiological activator of PAR 2 in the intestine and pancreas. PAR 2 is expressed at the apical and basolateral membrane of enterocytes [10] . Trypsin in the intestinal lumen signals to enterocytes by cleaving apical PAR 2 to induce generation of prostaglandins E 2 and F 1α . Inflammation of the pancreas leads to the premature activation of trypsins, which can signal to pancreatic acini and duct cells to control fluid and electrolyte transport [6, 11] , and to afferent nerves that express PAR 2 and which regulate inflammation and pain [12] .
Extrapancreatic trypsins
Trypsinogen IV was originally identified in human brain and may be a splice variant of mesotrypsinogen [13] . Brain trypsinogen IV may control expression of glial fibrillary acidic protein and process the amyloid precursor protein, but its mechanism of action is unknown [14] . We found that many extrapancreatic cell lines (PC-3, prostate; SW480, Caco2, colon; A549, airway) express PAR 2 , trypsinogen IV and enteropeptidase (N. Bunnett and G.S. Cottrell, unpublished work). We cloned and expressed trypsinogen IV and activated the zymogen with enteropeptidase. Trypsin IV induced a prompt increase in [Ca 2+ ] i (intracellular Ca 2+ concentration) in KNRK cells expressing human PAR 2 but not in nontransfected cells ( Figures 1A and 1B) , indicating that trypsin IV activates PAR 2 . Trypsin IV is resistant to proteinaceous inhibitors, which strongly inhibited trypsin I and II, and may thus signal for prolonged periods.
Tryptase
Tryptase is expressed by almost all subsets of human mast cells where it comprises up to 25% of cellular proteins and is released upon mast cell degranulation [15] . Purified human tryptase activates PAR 2 in transfected cells and cells that naturally express PAR 2 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (Figures 1C and 1D ). Recombinant α and βII tryptase can activate PAR 2 in BaF3 cells [17] , although βI tryptase does not activate PAR 2 [28] . Glycosylation of PAR 2 at Asn 30 , six residues proximal to the cleavage site, markedly impairs the capacity of tryptase to activate PAR 2 [29, 30] . Glycosylation may impede access of the N-terminus of PAR 2 to the active site in the centre of the tryptase tetrameric ring.
Tryptase is poorly diffusible and may signal to cells expressing PAR 2 in a paracrine manner. We investigated this possibility by co-culturing human mast cells that express tryptase and the IgE receptor with KNRK cells expressing PAR 2 
Coagulation factors
FVIIa and FXa can activate PAR 2 , but activity depends on the anchoring of these proteases to the cell surface in the vicinity of PAR 2 by tissue factor, an integral membrane protein that is normally expressed by extravascular cells, and which is expressed by endothelial cells and monocytes during inflammation [31, 32] . These mechanisms of signalling by FVIIa and FXa may be of particular importance during septic shock, when upstream coagulation proteases make a substantial contribution to the inflammatory response and when the expression of tissue factor is up-regulated.
PAR 2 : regulation of signal transduction
There are several unusual aspects of PAR signalling that provide insight into mechanisms that control signalling by GPCRs in general. Once cleaved the tethered ligand is always available to interact with the receptor, which would result in continuous stimulation unless there were efficient mechanisms to terminate this signalling. Proteolysis is an irreversible process and thus cleaved PARs can no longer be used by the cell and are degraded, a process termed downregulation, which unequivocally terminates signalling.
Desensitization and endocytosis of PAR 2 PAR 2 couples to G αq/11 , resulting in activation of phospholipase Cβ, production of inositol 1,4,5-trisphosphate and diacylglycerol, mobilization of Ca 2+ and activation of protein kinase C. These signalling events are rapidly attenuated and desensitize after repeated stimulation, indicative of receptor desensitization and down-regulation. β-Arrestins 1 and 2 are cytosolic proteins that mediate desensitization and endocytosis of many GPCRs. PAR 2 activation induces translocation of β-arrestins to the plasma membrane, where they interact with PAR 2 to mediate both desensitization and endocytosis [33, 34] . The GTPase dynamin mediates detachment of PAR 2 -containing clathrin-coated pits, and Rab5a mediates distal steps in endocytic trafficking of PAR 2 from clathrin-coated pits to early endosomes [35] .
Down-regulation of PAR 2
Internalized GPCRs may be degraded or can recycle. At one extreme, PARs, which are activated by irreversible proteolysis and are thus single-use receptors, traffic to lysosomes, a process termed down-regulation [36] . At the other extreme, receptors for neuropeptides such as the SP (substance P) receptor, which are activated by reversible peptide binding, can thus be reused, internalize and recycle to the cell surface [37] . The down-regulation of receptors is of fundamental importance in terminating signalling. However, little is known about the molecular mechanisms of post-endocytic sorting that target receptors for degradation.
Ubiquitination mediates down-regulation of growth factor receptors [38, 39] and GPCRs [40] [41] [42] . Although ubiquitination of growth factor receptors is important for endocytosis and post-endocytic sorting through proteasome or the multivesicular body/lysosome pathways, little is known about the mechanism and function of agonist-induced ubiquitination of GPCRs. We investigated ubiquitination of PAR 2 . Trypsin (10 nM, 15 min) induced ubiquitination of PAR 2 (Figure 2A) . Mutation of all six lysine residues in the C-terminus (PAR 2 δ6Lys/Ala) that are potential sites of ubiquitination abolished trypsin-stimulated ubiquitination. In cells expressing PAR 2 , trypsin (10 nM, 60 min) stimulated trafficking of PAR 2 to lysosomes ( Figure 2B ). In contrast, PAR 2 δ6Lys/Ala was not prominently localized in lysosomes at this time. Thus, PAR 2 is rapidly ubiquitinated within the C-terminus and ubiquitination is required for lysosomal trafficking but not endocytosis. Sustained signalling requires the mobilization of PAR 2 from prominent stores in the Golgi apparatus or synthesis of intact receptors [36] . Rab11a co-localizes in the Golgi apparatus with PAR 2 , and Rab11a mediates both recovery of PAR 2 at the cell surface and resensitization of PAR 2 signalling [35] .
Endocytosis and mitogenic signalling of PAR 2
MAPKs (mitogen-activated protein kinases) are organized into 'signalling modules' by tethering to scaffolding proteins and by direct interactions between the component kinases [43, 44] . This organization ensures physical segregation of the pathways and allows the same kinase to be used in more than (A) KNRK cells expressing PAR 2 -GFP (green fluorescent protein) or PAR 2 δ6Lys/Ala-GFP were incubated with 10 nM trypsin for 0-30 min. PAR 2 was precipitated with anti-GFP and blots were probed for ubiquitin. Note that PAR 2 -GFP underwent rapid and extensive ubiquitination after exposure to trypsin, whereas PAR 2 δ6Lys/Ala-GFP did not. (B) Cells were exposed to 10 nM trypsin for 60 min and PAR 2 was localized using GFP and LAMP1 (lysosomal-associated membrane protein-1) by immunofluorescence. Note that PAR 2 -GFP co-localizes with LAMP1 in lysosomes (yellow arrows) whereas PAR 2 δ6Lys/Ala-GFP is mostly excluded from lysosomes (white arrows). Scale bar, 10 µm. IP, immunoprecipitation; WB, Western blot; Ub, ubiquitin.
one MAPK module without affecting the function of other modules.
Activation of PAR 2 induces assembly of a MAPK signalling module by a mechanism that depends on β-arrestins [34] . PAR 2 agonists activate ERKs (extracellular-signalregulated kinases) 1/2, and activation is markedly inhibited by dominant-negative β-arrestin 319-418 . ERK1/2 remain in the cytosol and do not translocate to the nucleus to stimulate proliferation. The cytosolic retention of ERK1/2 depends on the formation of a multiprotein signalling complex (apparent mass of 250-300 kDa) that contains PAR 2 , β-arrestin 1, Raf-1 and pERK1/2 (phosphorylated SRK1/2). Other GPCRs can similarly interact with β-arrestin/Src/ MEK1 (MAPK/ERK kinase 1)/ERK1/2 modules that retain pERK1/2 in the cytosol [45] [46] [47] [48] .
PAR 2 : potential physiological and pathophysiological roles
Proteases that activate PAR 2 are generated and released during inflammation and accumulating evidence suggests a role for PAR 2 in inflammation and pain. 
PAR 2 and inflammation
A role for PAR 2 in inflammation is suggested by its up-regulation by tumour necrosis factor α, interleukin 1α and lipopolysaccharide [49, 50] . Deletion of PAR 2 also diminishes inflammation in the airway and joints [51, 52] . The proinflammatory effects of proteases could be mediated by activation of PAR 2 on multiple cell types (see [1, 2] ). However, recent studies indicate an important role of the nervous system in PAR 2 -mediated inflammation (Figure 3 ).
Neurogenic mechanisms of inflammation and pain
A subpopulation of primary sensory neurons of the dorsal root, trigeminal and vagal ganglia (C and A-δ) express the neuropeptides SP and CGRP (calcitonin-gene-related peptide). Noxious stimuli release SP and CGRP within tissues where they cause arteriolar vasodilatation, extravasation of plasma proteins from post-capillary venules, and adhesion of leucocytes to the venular endothelium ('neurogenic inflammation'). These same stimuli also induce the release of neuropeptides within the central nervous system, resulting in the central transmission of pain.
PAR 2 is co-expressed with SP and CGRP in rat dorsal root ganglia [22] . Activation of PAR 2 on primary spinal afferent neurons stimulates secretion of SP and CGRP from their projections in peripheral tissues and the spinal cord to cause neurogenic inflammation and thermal and mechanical hyperalgesia [22, [53] [54] [55] . The proteases that activate PAR 2 on sensory nerves during inflammation remains to be identified, but one possibility is tryptase from mast cells. Mast cells containing tryptase are in close proximity to sensory nerve endings in uninflamed and inflamed tissues [56] , and PAR 2 -deficient mice show diminished thermal hyperalgesia after mast cell degranulation [53] .
Inflammatory agents can potentiate responses to VR1 (vanilloid receptor-1), a member of the TRP (transient receptor potential) family of ion channels that is activated by protons, elevated temperature, certain lipids, and exogenous vanilloids such as capsaicin [57, 58] . TRPV1 (transient receptor potential vanilloid-like 1) mediates PAR 2 -induced thermal hyperalgesia [59] in part by a protein kinase Cdependent mechanism (N. Bunnett, unpublished work).
Conclusions
Considerable progress has been made in our understanding of PAR 2 . Several proteases have been identified that activate PAR 2 . Studies of PAR 2 signalling have provided insights into regulation of GPCRs in general. Observations in PAR 2 -deficient mice indicate that the receptor contributes to inflammation and pain. However, there is still much to learn. Almost nothing is known about the function and regulation of extrapancreatic trypsins. The mechanisms of PAR 2 downregulation are poorly understood. Most importantly from the standpoint of physiology and medicine, the optimal tools to study the function of PAR 2 -receptor antagonists -are lacking. It will be of great interest to investigate the contributions of proteases and PARs in experimental models of human disease using genetically modified animals and, when available, pharmacological antagonists.
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